Category - News

Markets

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...

March 8, 2023

Developments

LENZ Therapeutics in $83.5-million series B financing to advance presbyopia treatments

LENZ Therapeutics raised $83.5-million in an oversubscribed Series B financing. New investor, Sectoral Asset Management, led the financing and was joined by Alpha Wave Ventures and Point 72, as well as existing...

March 7, 2023

Developments

BioStem to acquire majority of assets of Auxocell Laboratories

BioStem Technologies (OTCQB:BSEM) agreed to acquire the majority of the assets of Auxocell Laboratories, a leading solid tissue processing equipment manufacturer. The Auxocell solid tissue processing device, AC:Px, is a...

March 7, 2023

Markets

Stifel starts Mineralys at buy; PT $45

Stifel launched coverage of Mineralys Therapeutics (NASDAQ:MLYS) with a “buy” rating and 12-month price target of $45. The stock closed at $18.96 on March 7. Mineralys’ lorundrostat is targeting hyperaldosteronism, a...

March 7, 2023

Developments

Hepion to update rencofilstat Phase 2 programs at NASH Congress

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CMO, Todd Hobbs, M.D., will be presenting, “Rencofilstat (CRV431): Update on NASH Clinical Program,” on March 3 at the 6th Global NASH Congress in London. Dr. Hobbs will be...

March 3, 2023

Developments

Hepion’s rencofilstat IP estate strengthened with new European patent

The European Patent Office granted a patent to Hepion Pharmaceuticals (NASDAQ:HEPA) covering the innovative formulation of Hepion’s lead cyclophilin inhibitor, rencofilstat. The newly granted European patent also...

March 2, 2023

Developments

FDA grants orphan drug to Aravive’s batiraxcept for pancreatic cancer

The FDA granted orphan drug designation for Aravive’s (NASDAQ:ARAV) batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC). In a statement, Gail McIntyre, Ph.D., DABT, CEO of Aravive, said three...

March 1, 2023

Markets

SVB starts Structure Therapeutics at OP; PT $33

SVB Securities initiated coverage of Structure Therapeutics (NASDAQ:GPCR) with an “outperform” rating and $33 price target. The stock closed at $24 on Feb. 27. “Our investment thesis is that the company’s platform and...

February 28, 2023

Markets

SVB starts Disc Medicine at OP; PT $36

SVB Securities launched coverage of Disc Medicine (NASDAQ:IRON) with an “outperform” rating and $36 price target. The stock closed at $24.39 on Feb. 27. Disc Medicine is a clinical-stage biopharmaceutical company...

February 28, 2023

Executive Moves

Heron names renowned healthcare investor Kevin Kotler to the board

Heron Therapeutics (NASDAQ:HRTX) appointed three new directors to the board, including Kevin Kotler, a renowned healthcare investor, founder and portfolio manager of Broadfin Capital. Mr. Kotler has over 30 years of...

February 24, 2023

Category - News

Subscribe